UPC

Business Context and Reporting Period

Company: Universe Pharmaceuticals INC (Nasdaq: UPC)
Reporting Period: Fiscal Year Ended September 30, 2025
Structure: Cayman Islands holding company with operations conducted through PRC subsidiaries (Jiangxi Universe, Universe Trade).
Business Model: Manufacturing and distribution of Traditional Chinese Medicine Derivatives (TCMD) and third-party pharmaceutical products, primarily targeting the elderly population in China.

Key Financial Metrics (Fiscal Year 2025)

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 22.4% year-over-year (YoY) to $17.86 million. This was driven by a 48.9% drop in third-party product sales due to China's centralized drug procurement policy lowering prices, partially offset by a slight increase in TCMD sales volume.
• Margin Expansion: Gross margin improved significantly to 35.3% from 26.4% in 2024. This was primarily due to a 20.9% decrease in the average unit cost of TCMD products following a supply recovery from 2023 floods, despite a 5.9% decrease in TCMD selling prices.
• Loss Reduction: Net loss narrowed by 57.9% to $3.67 million, driven by a 77.8% reduction in R&D expenses (completion of core technology projects) and a 41.3% reduction in selling expenses (reduced advertising spend).
• Capital Structure: The company raised $15.0 million in gross proceeds via a registered direct offering in December 2024. Outstanding debt increased to $9.26 million, with $9.26 million due within one year.

Guidance, Outlook, and Risks

• Capital Reorganization: Shareholders approved a capital reduction and share sub-division to reduce par value from $11.25 to $0.00001 and create a dual-class share structure (Class A and Class B). As of the filing date, the reorganization had not yet taken effect pending court registration.
• Construction Delays: A major construction-in-progress (CIP) project for new manufacturing facilities, originally budgeted at $23.2 million, has been delayed until June 30, 2028, due to regulatory changes regarding employee dormitories. An impairment of $481,109 was recognized on prepayments for this project.
• Liquidity: Management believes current cash ($33.6 million) and financing capabilities are sufficient for the next 12 months. However, the company relies on bank loans and related party guarantees (CEO guarantees) for working capital.
• Internal Controls: The company identified a material weakness in internal controls over financial reporting due to a lack of accounting staff with U.S. GAAP expertise. Remediation efforts are underway.
• Regulatory Risks: Significant risks exist regarding PRC government oversight, data security regulations, and the potential for delisting under the Holding Foreign Companies Accountable Act if the PCAOB cannot inspect the auditor (though the current auditor is based in Singapore and subject to inspection).

Investor Verification Checklist

• Capital Reorganization Status: Verify if the capital reduction and share sub-division have been finalized and registered with the Cayman Islands Registrar of Companies.
• Debt Refinancing: Confirm the ability to refinance $9.26 million in debt due within one year, given the company's recurring losses and reliance on CEO personal guarantees.
• Internal Control Remediation: Monitor progress on hiring U.S. GAAP-qualified accounting staff to address the material weakness in financial reporting.
• Construction Project Viability: Assess the financial impact of the CIP project delay to 2028 and the $481k impairment charge on future cash flow requirements.
• Revenue Sustainability: Evaluate the long-term impact of China's centralized drug procurement policy on third-party product margins and sales volumes.